Figure 3.

Switching TNF inhibitors: ACR response 12 weeks after switching to adalimumab. Data from Bombardieri et al. [25]. ACR, American College of Rheumatology; TNF, tumour necrosis factor.

Rubbert-Roth and Finckh Arthritis Research & Therapy 2009 11(Suppl 1):S1   doi:10.1186/ar2666